Table 3.
ARISTOTLE | RE-LY | |||
C-index | 95% CI | C-index | 95% CI | |
Major bleeding | ||||
All | 0.677 | 0.657 to 0.698 | 0.708 | 0.684 to 0.731 |
Asia/Pacific | 0.684 | 0.639 to 0.728 | 0.649 | 0.558 to 0.739 |
Europe | 0.680 | 0.641 to 0.719 | 0.701 | 0.664 to 0.739 |
Latin America | 0.674 | 0.629 to 0.719 | 0.657 | 0.561 to 0.754 |
North America | 0.659 | 0.620 to 0.699 | 0.710 | 0.672 to 0.749 |
Other | 0.760 | 0.698 to 0.822 |
ABC-AF bleeding score, Age, Biomarkers (troponin T-hs, haemoglobin, and GDF-15), Clinical history (previous bleeding); ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; RE-LY, Randomized Evaluation of Long-Term Anticoagulation Therapy.